Table 1 Baseline characteristics of 58 patients with COVID-19.
Items | MSC group | Placebo group | P value | 95% CI |
|---|---|---|---|---|
Enrolled number | ||||
29 | 29 | 1.000 | ||
Gender | ||||
Men | 12 (41.4) | 10 (34.5) | 0.7871 | |
Female | 17 (58.6) | 19 (65.5) | – | |
Age | ||||
Median | 64 (54.5, 68) | 66 (59.5, 69.5) | 0.2221 | −7.418 to 1.763 |
>50 (number, %) | 24 (82.8) | 28 (96.6) | 0.194 | |
30–50 (number, %) | 5 (17.2) | 1 (3.4) | 0.194 | |
COVID-19 type | ||||
Common/mild | 15 (51.7) | 16 (55.2) | 1.000 | |
Severe | 11 (37.9) | 10 (34.5) | 1.000 | |
Critical | 3 (10.3) | 3 (10.3) | 1.000 | |
Comorbidities | ||||
Coronary heart disease | 3 (10.3) | 3 (10.3) | 1.000 | |
Diabetes | 4 (13.8) | 4 (13.8) | 1.000 | |
Cerebrovascular disease | 3 (10.3) | 2 (6.9) | 1.000 | |
Hypertension | 12 (41.4) | 11 (37.9) | 1.000 | |
Chronic respiratory disease | 1 (3.4) | 0 (0) | 1.000 | |
History of liver and kidney disease | 2 (6.9) | 3 (10.3) | 1.000 | |
Admission symptoms | ||||
Cough | 22 (75.9) | 21 (72.4) | 1.000 | |
Fever | 16 (55.2) | 20 (69.0) | 0.417 | |
Anhelation | 17 (58.6) | 16 (55.2) | 0.730 | |
Chest distress | 11 (37.9) | 14 (48.3) | 0.596 | |
Fatigue | 21 (72.4) | 19 (65.5) | 1.000 | |
Muscular soreness | 9 (31.0) | 5 (17.2) | 0.358 | |
Poor appetite | 3 (10.3) | 5 (17.2) | 0.787 | |
Diarrhea | 3 (10.3) | 3 (10.3) | 1.000 | |
Dizziness | 2 (6.9) | 5 (17.2) | 0.423 | |
Nausea and vomiting | 3 (10.3) | 3 (10.3) | 1.000 | |
Time from symptom onset to starting study treatment | ||||
Days | 13 (9.5, 15.5) | 11 (8, 14.5) | 0.6908 | −2.628 to 3.939 |
Admission laboratory data | ||||
Total bilirubin (μmol/L) | 11.1 (9.16, 15.2) | 10.9 (9.05, 13.8) | 0.6355 | −3.722 to 2.292 |
C-reative protein (mg/L) | 51.4 (18.3, 100.6) | 55.2 (32.0, 110.2) | 0.2648 | −14.14 to 50.33 |
Procalcitonin (ng/mL) | 0.10 (0.04, 0.14) | 0.09 (0.04, 0.17) | 0.2887 | −0.1216 to 0.4002 |
WBC (/uL) | 6.31 (4.20, 7.37) | 6.75 (4.92, 8.64) | 0.0781 | −4.211 to 0.2313 |
Neutrophils (/uL) | 5.66 (3.40, 7.48) | 4.34 (2.91, 5.95) | 0.0938 | −3.142 to 0.2534 |
Lymphocyte (/uL) | 0.64 (0.42, 1.12) | 0.93 (0.54, 1.24) | 0.1827 | −0.08833 to 0.4521 |
Monocytes (/uL) | 0.25 (0.19, 0.48) | 0.30 (0.20, 0.44) | 0.5397 | −0.2566 to 0.4848 |
Hemoglobin (g/L) | 130 (114, 145) | 126 (119, 136) | 0.8587 | −8.995 to 7.521 |
Platelet (/uL) | 162 (143–238) | 208 (158, 254) | 0.4755 | −26.03 to 55.1 |
Alanine aminotransferase (U/L) | 40.0 (29.5–63.4) | 32.5 (23.2, 47.8) | 0.8469 | −26.15 to 21.54 |
Aspartate aminotransferase (U/L) | 31.9 (27.3–47.5) | 33.4 (23.5, 47.3) | 0.7854 | −20.64 to 15.69 |
Creatinine (mg/dL) | 62.9 (47.0–80.5) | 61.8 (53.1, 81.4) | 0.1683 | −118.6 to 21.23 |
Serum potassium (mmol/L) | 3.73 (3.46–3.88) | 3.79 (3.55, 4.13) | 0.2792 | −0.1147 to 0.3897 |
Serum sodium (mmol/L) | 139 (137–141) | 139 (135–141) | 0.8151 | −2.961 to 2.339 |
Activated partial prothrombin time (s) | 27.5 (25.0–31.7) | 28.9 (26.2–32.2) | 0.5698 | −1.655 to 2.975 |
Fibrinogen (g/s) | 4.60 (3.42–4.98) | 4.59 (3.94–5.17) | 0.522 | −0.4026 to 0.7837 |
